TY - JOUR

T1 - Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action

AU - Manchia, Mirko

AU - Vieta, Eduard

AU - Smeland, Olav B.

AU - Altimus, Cara

AU - Bechdolf, Andreas

AU - Bellivier, Frank

AU - Bergink, Veerle

AU - Fagiolini, Andrea

AU - Geddes, John R.

AU - Hajek, Tomas

AU - Henry, Chantal

AU - Kupka, Ralph

AU - Lagerberg, Trine V.

AU - Licht, Rasmus W.

AU - Martinez-Cengotitabengoa, Monica

AU - Morken, Gunnar

AU - Nielsen, René E.

AU - Pinto, Ana Gonzalez

AU - Reif, Andreas

AU - Rietschel, Marcella

AU - Ritter, Phillip

AU - Schulze, Thomas G.

AU - Scott, Jan

AU - Severus, Emanuel

AU - Yildiz, Aysegul

AU - Kessing, Lars Vedel

AU - Bauer, Michael

AU - Goodwin, Guy M.

AU - Andreassen, Ole A.

AU - for the European College of Neuropsychopharmacology (ECNP) Bipolar Disorders Network

N1 - Correction: https://doi.org/10.1016/j.euroneuro.2021.01.001

PY - 2020

Y1 - 2020

N2 - Bipolar disorder (BD) is a major healthcare and socio-economic challenge. Despite its substantial burden on society, the research activity in BD is much smaller than its economic impact appears to demand. There is a consensus that the accurate identification of the underlying pathophysiology for BD is fundamental to realize major health benefits through better treatment and preventive regimens. However, to achieve these goals requires coordinated action and innovative approaches to boost the discovery of the neurobiological underpinnings of BD, and rapid translation of research findings into development and testing of better and more specific treatments. To this end, we here propose that only a large-scale coordinated action can be successful in integrating international big-data approaches with real-world clinical interventions. This could be achieved through the creation of a Global Bipolar Disorder Foundation, which could bring government, industry and philanthropy together in common cause. A global initiative for BD research would come at a highly opportune time given the seminal advances promised for our understanding of the genetic and brain basis of the disease and the obvious areas of unmet clinical need. Such an endeavour would embrace the principles of open science and see the strong involvement of user groups and integration of dissemination and public involvement with the research programs. We believe the time is right for a step change in our approach to understanding, treating and even preventing BD effectively.

AB - Bipolar disorder (BD) is a major healthcare and socio-economic challenge. Despite its substantial burden on society, the research activity in BD is much smaller than its economic impact appears to demand. There is a consensus that the accurate identification of the underlying pathophysiology for BD is fundamental to realize major health benefits through better treatment and preventive regimens. However, to achieve these goals requires coordinated action and innovative approaches to boost the discovery of the neurobiological underpinnings of BD, and rapid translation of research findings into development and testing of better and more specific treatments. To this end, we here propose that only a large-scale coordinated action can be successful in integrating international big-data approaches with real-world clinical interventions. This could be achieved through the creation of a Global Bipolar Disorder Foundation, which could bring government, industry and philanthropy together in common cause. A global initiative for BD research would come at a highly opportune time given the seminal advances promised for our understanding of the genetic and brain basis of the disease and the obvious areas of unmet clinical need. Such an endeavour would embrace the principles of open science and see the strong involvement of user groups and integration of dissemination and public involvement with the research programs. We believe the time is right for a step change in our approach to understanding, treating and even preventing BD effectively.

KW - Machine learning

KW - Open science

KW - Philanthropy

KW - Precision medicine

KW - Risk prediction

U2 - 10.1016/j.euroneuro.2020.05.006

DO - 10.1016/j.euroneuro.2020.05.006

M3 - Journal article

C2 - 32536571

AN - SCOPUS:85086475356

VL - 36

SP - 121

EP - 136

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

ER -